Cytokine-induced killer cell therapy (Sabz Biomedicals)

N/A

Report date: 2024/11/08 20:00:30

Base Information

Drug NameCytokine-induced killer cell therapy (Sabz Biomedicals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cellCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSabz Biomedicals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSabz Biomedicals

Active IndicationsN/A

Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A